Journal
PROSTATE
Volume 73, Issue 11, Pages 1171-1181Publisher
WILEY
DOI: 10.1002/pros.22665
Keywords
translational biomarkers; metabolism, metabolic flux; magnetic resonance spectroscopy
Categories
Funding
- Department of Defense Synergistic Idea Development Award [W81XWH-10-1-0334]
- Peer Reviewed Cancer Research Concept Award
- National Institute of Health [P41 EB013598, K99 EB014328, R01 CA166766]
- [W81XWH-12-1-0328]
Ask authors/readers for more resources
BACKGROUND. The treatment of prostate cancer has been impeded by the lack of both clinically relevant disease models and metabolic markers that track tumor progression. Hyperpolarized (HP) C-13 MR spectroscopy has emerged as a new technology to investigate the metabolic shifts in prostate cancer. In this study, we investigate the glucose reprogramming using HP C-13 pyruvate MR in a patient-derived prostate tissue slice culture (TSC) model. METHODS. The steady-state metabolite concentrations in freshly excised human prostate TSCs were assessed and compared to those from snap-frozen biopsy samples. The TSCs were then applied to a perfused cell (bioreactor) platform, and the bioenergetics and the dynamic pyruvate flux of the TSCs were investigated by P-31 and HP C-13 MR, respectively. RESULTS. The prostate TSCs demonstrated steady-state glycolytic and phospholipid metabolism, and bioenergetics that recapitulate features of prostate cancer in vivo. C-13 spectra following injection of HP C-13 pyruvate showed significantly increased pyruvate to lactate flux in malignant as compared to the benign prostate TSCs. This increased flux in the malignant prostate TSCs correlated with both increased expression of monocarboxylate transporters (MCT) and activity of lactate dehydrogenase (LDH). CONCLUSIONS. We provide the first mechanistic evidence for HP C-13 lactate as a prostate cancer biomarker in living human tissues, critical for the interpretation of in vivo studies. More broadly, the clinically relevant metabolic model system in combination with HP MR can facilitate the identification of clinically translatable biomarkers of prostate cancer presence, aggressiveness, and treatment response. (C) 2013 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available